Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sahai Donaldson, Richard Ogunti, Angesom Kibreab & Alem Mehari. (2020) Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy. Core Evidence 15, pages 31-40.
Read now
Read now
Robert Dufour, Janis Pruett, Nan Hu, Cassandra Lickert, Stephen Stemkowski, Yuen Tsang, Daniel Lane & William Drake$suffix/text()$suffix/text(). (2017) Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. Journal of Medical Economics 20:11, pages 1178-1186.
Read now
Read now
Samuel Johnson, Thomas Delate, Adrian Boka, Paul Shaw & Carol Zager. (2013) Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system. Journal of Medical Economics 16:12, pages 1414-1422.
Read now
Read now
Articles from other publishers (29)
Hilary M. DuBrock, Hayley D. Germack, Marjolaine Gauthier-Loiselle, Jörg Linder, Ambika Satija, Ameur M. Manceur, Martin Cloutier, Patrick Lefebvre, Sumeet Panjabi & Robert P. Frantz. (2023) Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH). PharmacoEconomics - Open.
Crossref
Crossref
Barbro Kjellström, Hannes Runheim, Amélie Beaudet, Magnus Husberg, Bodil Ivarsson, Nadia Pillai, Lars‐Åke Levin & Lars Bernfort. (2023) Societal costs associated to chronic thromboembolic pulmonary hypertension: A study utilizing linked national registries. Pulmonary Circulation 13:2.
Crossref
Crossref
Yuen Tsang, Sumeet Panjabi, Vienica Funtanilla, Hayley D. Germack, Marjolaine Gauthier‐Loiselle, Ameur M. Manceur, Stephanie Liu, Martin Cloutier & Patrick Lefebvre. (2023) Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). Pulmonary Circulation 13:2.
Crossref
Crossref
V.D. Zakiev, T.V. Martynyuk, A.A. Vedernikov, D.A. Petrenko & S.V. Korkach-Romanov. (2023) Socio-economic burden of newly diagnosed pulmonary arterial hypertension and early specific treatment initiation impact on the costs in real clinical practice in Russia. Medical Technologies. Assessment and Choice:1, pages 99.
Crossref
Crossref
Hannes Runheim, Barbro Kjellström, Amélie Beaudet, Bodil Ivarsson, Magnus Husberg, Nadia Pillai, Lars‐Åke Levin & Lars Bernfort. (2023) Societal costs associated with pulmonary arterial hypertension: A study utilizing linked national registries. Pulmonary Circulation 13:1.
Crossref
Crossref
Néboa Zozaya, Fernando Abdalla, Ignacio Casado Moreno, Carlos Crespo-Diz, Ana M. Ramírez Gallardo, Joaquín Rueda Soriano, Macarena Alcalá Galán & Álvaro Hidalgo-Vega. (2022) The economic burden of pulmonary arterial hypertension in Spain. BMC Pulmonary Medicine 22:1.
Crossref
Crossref
Jasleen Minhas, Sai Prasanna Narasimmal, Todd M. Bull, Teresa De Marco, John Wesley McConnell, Matthew R. Lammi, Thenappan Thenappan, Jeremy P. Feldman, Jeffrey S. Sager, David B. Badesch, John J. Ryan, Daniel C. Grinnan, Dianne Zwicke, Evelyn M. Horn, Jean M. Elwing, John E. Moss, Michael Eggert, Oksana A. Shlobin, Robert P. Frantz, Sonja D. Bartolome, Stephen C. Mathai, Sula Mazimba, Steven C. Pugliese & Nadine Al‐Naamani. (2021) Health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR). Pulmonary Circulation 11:4, pages 1-11.
Crossref
Crossref
Sandeep Sahay, Yuen Tsang, Megan Flynn, Peter Agron & Robert Dufour. (2020) Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study. Pulmonary Circulation 10:4, pages 1-9.
Crossref
Crossref
Viviane P. Sprecher, Eva‐Maria Didden, Joel N. Swerdel & Audrey Muller. (2020) Evaluation of code‐based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases. Pulmonary Circulation 10:4, pages 1-10.
Crossref
Crossref
Scott A. Helgeson, Divya Menon, Haytham Helmi, Charitha Vadlamudi, John E. Moss, Tonya K. Zeiger & Charles D. Burger. (2020) Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension. Diseases 8:2, pages 22.
Crossref
Crossref
Stefanie E. Mason, Jinyi Zhu, Farbod N. Rahaghi, George R. Washko & Ankur Pandya. (2020) Cost-effectiveness microsimulation of catheter-directed thrombolysis in submassive pulmonary embolism using a right ventricular function model. Journal of Thrombosis and Thrombolysis 49:4, pages 673-680.
Crossref
Crossref
V. D. Zakiev, A. D. Gvozdeva & T. V. Martynyuk. (2020) Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world. Terapevticheskii arkhiv 92:3, pages 125-131.
Crossref
Crossref
Shraddha Narechania, Heather Torbic & Adriano R. Tonelli. (2019) Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics 25:2, pages 131-141.
Crossref
Crossref
Kathleen Morrisroe, Wendy Stevens, Joanne Sahhar, Gene-Siew Ngian, Nava Ferdowsi, Dylan Hansen, Shreeya Patel, Catherine L. Hill, Janet Roddy, Jennifer Walker, Susanna Proudman & Mandana Nikpour. (2019) The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. BMC Pulmonary Medicine 19:1.
Crossref
Crossref
Emmanuel Bergot, Lucie De Leotoing, Hakim Bendjenana, Charlène Tournier, Alexandre Vainchtock, Gaëlle Nachbaur & Marc Humbert. (2019) Hospital burden of pulmonary arterial hypertension in France. PLOS ONE 14:9, pages e0221211.
Crossref
Crossref
Stephen C. Mathai, Anna Ryan Hemnes, Scott Manaker, Rebekah H. Anguiano, Bonnie B. Dean, Vishal Saundankar, Peter Classi, Andrew C. Nelsen, Kathryn Gordon & Corey E. Ventetuolo. (2019) Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms. Annals of the American Thoracic Society 16:7, pages 797-806.
Crossref
Crossref
V. Cottin, D. Avot, L. Lévy-Bachelot, C. A. Baxter, D. R. Ramey, L. Catella, S. Bénard, O. Sitbon & S. Teal. (2019) Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database. PLOS ONE 14:4, pages e0214649.
Crossref
Crossref
Sean Studer, Michael Hull, Janis Pruett, Eleena Koep, Yuen Tsang & William DrakeIIIIII. (2018) Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real‐world US database. Pulmonary Circulation 9:1, pages 1-12.
Crossref
Crossref
Richmond Robinson, T. Craig Wirt, Carolina Barbosa, Arezou Amidi, Shirley Chen, Robert M. Joseph & Adam E. Fleischer. (2018) Routine Use of Low-Molecular-Weight Heparin For Deep Venous Thrombosis Prophylaxis After Foot and Ankle Surgery: A Cost-Effectiveness Analysis. The Journal of Foot and Ankle Surgery 57:3, pages 543-551.
Crossref
Crossref
Charles D. BurgerJanis A. PruettCassandra A. LickertAriel BergerBrian MurphyWilliam DrakeIIIIII. (2018) Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. Journal of Managed Care & Specialty Pharmacy 24:3, pages 291-302.
Crossref
Crossref
Kelly Comerford Wormer, Ayesha A. Jangda, Farah A. El aayed, Katherine I. Stewart, Sunni L. Mumford & James H. Segars. (2018) Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: a systematic review and cost analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology.
Crossref
Crossref
George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett & William Drake. (2018) Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy. Journal of Health Economics and Outcomes Research 5:2, pages 206-219.
Crossref
Crossref
Gustavo A. Heresi, David M. Platt, Wenyi Wang, Christine H. Divers, Vijay N. Joish, Simon A. Teal & Justin S. Yu. (2017) Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulmonary Medicine 17:1.
Crossref
Crossref
Annie‐Christine Lajoie, Sebastien Bonnet & Steeve Provencher. (2017) Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation 7:2, pages 312-325.
Crossref
Crossref
Christine DiversDavid PlattEdward WangJay LinMelissa Lingohr-SmithStephen C. Mathai. (2017) A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States. Journal of Managed Care & Specialty Pharmacy 23:1, pages 92-104.
Crossref
Crossref
Shuyan Gu, Huimei Hu & Hengjin Dong. (2015) Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics 34:6, pages 533-550.
Crossref
Crossref
Mirko Sikirica, Serban R Iorga, Tim Bancroft & Jesse Potash. (2014) The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Services Research 14:1.
Crossref
Crossref
Bernd Schweikert, David Pittrow, Carmine Dario Vizza, Joanna Pepke-Zaba, Marius M Hoeper, Anja Gabriel, Jenny Berg & Mirko Sikirica. (2014) Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. BMC Health Services Research 14:1.
Crossref
Crossref
Charles D Burger, Pamela K Long, Monarch R Shah, Michael D McGoon, Dave P Miller, Alain J Romero, Wade W Benton & Robert E Safford. (2014) Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry. Chest 146:5, pages 1263-1273.
Crossref
Crossref